Halozyme Therapeutics, Inc. (HALO)
121.84
+0.33
(+0.27%)
USD |
NASDAQ |
Oct 16, 16:00
121.37
-0.47
(-0.39%)
After-Hours: 20:00
Halozyme Therapeutics Cash from Investing (Quarterly) : -62.66M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -62.66M |
| March 31, 2026 | -2.877M |
| December 31, 2025 | -741.79M |
| September 30, 2025 | 201.61M |
| June 30, 2025 | 84.79M |
| March 31, 2025 | -90.42M |
| December 31, 2024 | 29.48M |
| September 30, 2024 | -167.48M |
| June 30, 2024 | -42.04M |
| March 31, 2024 | -82.68M |
| December 31, 2023 | -8.291M |
| September 30, 2023 | -83.45M |
| June 30, 2023 | 54.99M |
| March 31, 2023 | -60.16M |
| December 31, 2022 | -1.746M |
| September 30, 2022 | -1.008M |
| June 30, 2022 | -434.95M |
| March 31, 2022 | -49.30M |
| December 31, 2021 | -299.47M |
| September 30, 2021 | -16.95M |
| June 30, 2021 | -44.62M |
| March 31, 2021 | -45.25M |
| December 31, 2020 | 58.44M |
| September 30, 2020 | -30.10M |
| June 30, 2020 | 11.90M |
| Date | Value |
|---|---|
| March 31, 2020 | 38.11M |
| December 31, 2019 | -122.82M |
| September 30, 2019 | 41.00M |
| June 30, 2019 | 47.46M |
| March 31, 2019 | 28.81M |
| December 31, 2018 | 10.81M |
| September 30, 2018 | 35.19M |
| June 30, 2018 | -7.607M |
| March 31, 2018 | -35.90M |
| December 31, 2017 | -148.99M |
| September 30, 2017 | 30.28M |
| June 30, 2017 | -49.29M |
| March 31, 2017 | 4.265M |
| December 31, 2016 | 21.04M |
| September 30, 2016 | 8.246M |
| June 30, 2016 | -0.435M |
| March 31, 2016 | -105.62M |
| December 31, 2015 | -14.76M |
| September 30, 2015 | 20.29M |
| June 30, 2015 | 10.77M |
| March 31, 2015 | -10.42M |
| December 31, 2014 | 13.48M |
| September 30, 2014 | 2.628M |
| June 30, 2014 | -5.87M |
| March 31, 2014 | -43.19M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| AVITA Medical, Inc. | 3.947M |
| Iovance Biotherapeutics, Inc. | -74.05M |
| Merck & Co., Inc. | -5.602B |
| Incyte Corp. | -51.79M |
| Agenus, Inc. | 0.267M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 240.89M |
| Cash from Financing (Quarterly) | -326.25M |
| Free Cash Flow | 806.22M |
| Free Cash Flow Per Share (Quarterly) | 1.953 |
| Free Cash Flow to Equity (Quarterly) | 234.70M |
| Free Cash Flow to Firm (Quarterly) | 241.23M |
| Free Cash Flow Yield | 5.47% |